BusinessWire · Jan 2026
Announces PEGASUS™, a multimodal AI model for engineering cell-permeable macrocyclic peptides and highlights the first reported permeable peptides with more than two polar or ionizable fragments.
Multimodal AI Platform for Modality Agnostic Drug Discovery™
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
1910 is a Boston-based AI-native biotechnology company (formerly 1910 Genetics) building a multimodal drug-discovery platform that combines proprietary biological/computational data, frontier AI, and lab automation to design small- and large-molecule therapeutics.
Primary product
ITO™ platform for AI-enabled drug discovery
Founded
2018
Headquarters
451 D St., Suite 905, Boston, MA 02210, United States
Team size
11-50
Industry
Biotechnology Research
Sub-industry
AI-enabled drug discovery / TechBio
Offices
Boston Seaport District, Boston, MA
Cambridge, MA
Business model
co-discovery
co-engineering
platform-as-a-service
asset licensing
data licensing
Funding
Stage
Series A-2
Total raised
$40M
Latest round
Series A-2 · Oct 2024
Oct 2024 · Accenture Ventures
Sep 2021 · NIH
Mar 2021 · M12 (Microsoft’s Venture Fund) and Playground Global
Mar 2020 · Sam Altman
People & investors
Leadership
Founder & CEO
Chief Scientific Officer
Head of AI Research & ML Engineering
Director of Medicinal Chemistry
Director of Biology
Philip A. Woodburn, CPA, MBA
Sr. Director of Strategic Finance & Corporate Development
Senior Director of Finance and Operations
Kyle Barbato
Interim Head of Talent Acquisition
Associate Manager of Talent Acquisition
Work & culture
Mission-driven, high-ownership culture with a strong hiring bar ('top 1% talent'), founder's mentality, urgency, teamwork, communication, grit, integrity, and explicit DEI commitments.
Visa sponsorship
Limited
Compensation
Public job posts describe a competitive compensation package, above-market benefits, generous vacation and parental leave, team-building activities, and great colleagues.
Benefits
Competitive compensation package
Above-market benefits
Generous vacation and parental leave
Team-building activities
Great colleagues
Product & market
Pricing
Enterprise partnership pricing through co-discovery, co-engineering, platform-as-a-service, and licensing arrangements.
Differentiators
- —Proprietary ITO™ platform combining multimodal data, AI, and lab automation
- —Three proprietary data streams: computational, wet-lab proxy, and wet-lab ground truth data
- —Federated learning to build models without sharing raw private data
- —Modality-agnostic discovery across small and large molecules
- —Hundreds of AI models organized in a multi-AI-agent system
Technology
Microsoft Azure
Azure Quantum Elements
NVIDIA
federated learning
multi-AI agent system
model foundry
high-throughput lab automation
GROMACS
Schrödinger
Python
bash
Docker
Kubernetes
GitHub
React
PostgreSQL
MongoDB
OpenAI
Customers
Pharmaceutical companies
Biotechnology companies
Government institutions
Academic institutions
Research institutions
Scale & contact
Estimated revenue
$1M-$10M
Latest news
BusinessWire · Nov 2025
Publishes CANDID-CNS™, which predicts BBB penetration for bRo5 molecules and incorporates stereochemistry; the company says it outperforms Pfizer's CNS MPO benchmarks on several tasks.
1910.ai press release · Oct 2024
Accenture Ventures invested in 1910 and joined advisory boards; the partnership expands commercialization of the ITO platform for biopharma R&D.
Inc. · Mar 2024
Profile of Jen Asher and 1910's mission, growth, and Microsoft partnership; includes context on the company's Boston Seaport footprint and founding story.
1910.ai press release · Feb 2024
Announces a five-year commercial agreement with Microsoft to combine 1910's data and lab automation with Azure Quantum Elements for drug discovery.
Jobs and careers at 1910
1 job at 1910
Safety Coordinator
On-site
Operations
Denver; Denver, Colorado, United States
1mo ago
On-site
Full-time